🚀 VC round data is live in beta, check it out!

Galenica Valuation Multiples

Discover revenue and EBITDA valuation multiples for Galenica and similar public comparables like Sigma Foods, WPG Holdings, SiteOne, MSC Industrial Direct and more.

Galenica Overview

About Galenica

Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers.


Founded

1927

HQ

Switzerland

Employees

8.0K

Financials (LTM)

Revenue: $5B
EBITDA: $440M

EV

$5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Galenica Financials

Galenica reported last 12-month revenue of $5B and EBITDA of $440M.

In the same LTM period, Galenica generated $1B in gross profit, $440M in EBITDA, and $231M in net income.

Revenue (LTM)


Galenica P&L

In the most recent fiscal year, Galenica reported revenue of $5B and EBITDA of $445M.

Galenica is profitable as of last fiscal year, with gross margin of 27%, EBITDA margin of 8%, and net margin of 4%.

See analyst estimates for Galenica
LTMLast FY202320242025202620272028
Revenue$5B$5B$5B$5B$5B
Gross Profit$1B$1B$1B$1B$1B
Gross Margin27%27%28%28%28%
EBITDA$440M$445M$389M$426M$445M
EBITDA Margin8%8%8%9%9%
EBIT Margin6%6%5%5%5%
Net Profit$231M$234M$361M$231M$229M
Net Margin4%4%8%5%4%

Financial data powered by Morningstar, Inc.

Galenica Stock Performance

Galenica has current market cap of $5B, and enterprise value of $5B.

Market Cap Evolution


Galenica's stock price is $105.31.

Galenica share price decreased by 3.0% in the last year.

Galenica has an EPS (earnings per share) of $4.69.

See more trading valuation data for Galenica
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5B$5B0.4%-14.4%-3.0%$4.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Galenica Valuation Multiples

Galenica trades at 1.0x EV/Revenue multiple, and 12.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Galenica

EV / Revenue (LTM)


Galenica Financial Valuation Multiples

As of May 1, 2026, Galenica has market cap of $5B and EV of $5B.

Galenica has a P/E ratio of 22.7x.

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.0x1.1x1.1x1.0x
EV/EBITDA12.3x12.1x13.9x12.7x12.1x
EV/EBIT17.7x17.9x22.5x20.9x18.9x
EV/Gross Profit3.7x3.7x4.1x3.9x3.7x
P/E22.7x22.5x14.5x22.7x22.9x
EV/FCF18.6x17.5x28.6x22.2x17.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Galenica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Galenica Margins & Growth Rates

Galenica grew revenue by 4% and EBITDA by 1% in the last fiscal year.

In the most recent fiscal year, Galenica reported gross margin of 27%, EBITDA margin of 8%, and net margin of 4%.

See estimated margins and future growth rates for Galenica

Galenica Margins

Last FY202420252026202720282029
Gross Margin27%28%28%25%
EBITDA Margin8%9%9%8%
EBIT Margin6%5%5%6%
Net Margin4%5%4%4%
FCF Margin6%5%6%5%

Galenica Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%5%5%6%
Gross Profit Growth(6%)4%6%(6%)
EBITDA Growth1%10%4%1%
EBIT Growth2%8%11%8%
Net Profit Growth(3%)(36%)(1%)(1%)
FCF Growth(12%)29%27%(12%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Galenica Operational KPIs

Galenica's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.1M for the same period.

Galenica's Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Galenica's Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Galenica
LTMLast FY202320242025202620272028
Rule of 4012%14%
Bessemer Rule of X19%24%
Revenue per Employee$0.7M
Opex per Employee$0.1M
S&M Expenses to Revenue1%1%1%1%
G&A Expenses to Revenue1%2%1%1%
Opex to Revenue22%23%23%22%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Galenica Competitors

Galenica competitors include Sigma Foods, WPG Holdings, SiteOne, MSC Industrial Direct, MonotaRO, Bidvest Group, SFS Group, Reece, Synnex Group and Resideo.

Most Galenica public comparables operate across Wholesale Distribution.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sigma Foods0.8x0.8x6.3x7.1x
WPG Holdings0.3x0.3x12.2x12.2x
SiteOne1.4x1.4x17.5x15.6x
MSC Industrial Direct1.7x1.6x16.4x14.2x
MonotaRO2.6x2.5x16.5x15.8x
Bidvest Group0.9x0.9x7.7x7.4x
SFS Group1.5x1.5x9.9x9.7x
Reece1.2x1.2x12.3x11.9x

This data is available for Pro users. Sign up to see all Galenica competitors and their valuation data.

Start Free Trial

Galenica M&A Activity

Galenica has acquired 4 companies to date.

Last acquisition by Galenica was on September 10th 2025. Galenica acquired labor team for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Galenica

labor team
Aquantic AG
Bichsel Group
Relypsa
Description
Labor Team is a Swiss medical laboratory specializing in diagnostics across microbiology, clinical chemistry, hematology, and immunology. Based in Bern, it employs specialists like Prof. Dr. med. Guido Funke and Prof. Dr. med. Johannes Haybäck to deliver precise testing for hospitals and clinics nationwide. The facility processes routine and specialized analyses with rapid turnaround times.
Aquantic AG is a software provider in the healthcare industry, offering SmartMIP as a cloud-based interface between pharmaceutical firms and health insurers in Switzerland. The platform handles individual negotiations, condition agreements via rating lists, case-specific reclaims, pricing model definitions, and related reclaims. Zug-headquartered, the company streamlines rebate management and contract settlements to support efficient pharmaceutical pricing and reimbursement processes.
Bichsel Group is an Interlaken-headquartered Swiss manufacturer specializing in customized medicines and medical devices. It produces individual dosage forms like capsules, ointments, and suppositories for pharmacies unable to compound in-house. The group supplies sterile injectables and ophthalmics under GMP standards. Operating since 1949, Bichsel serves hospitals and clinics across Switzerland with a production facility exceeding 5,000 square meters.
Relypsa is a biopharmaceutical company developing non-absorbed polymeric drugs for cardiorenal diseases. Its lead product, patiromer, treats hyperkalemia in CKD patients. Redwood City, California-headquartered Relypsa focuses on iron deficiency and nephrology therapies. Acquired by Gilead in 2016 for $1.3 billion, it markets Veltassa globally.
HQ CountrySwitzerlandSwitzerlandSwitzerlandUnited States
HQ City
Goldach
Basel
Interlaken
San Francisco, CA
Deal Date10 Sep 202511 Jul 202230 Apr 201921 Jul 2016
Valuationundisclosed$10Mundisclosed$2B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Galenica acquisitions and their M&A valuation multiples.

Start Free Trial

Galenica Investment Activity

Galenica has invested in 1 company to date.

Latest investment by Galenica was on January 25th 2023. Galenica invested in TOM Medications in their $1M Strategic investment round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Galenica

TOM Medications
TOM Medications
Description
TOM Medications is a platform managing therapy and medications for 400,000 patients while supplying pharmaceutical and healthcare sectors with real-world data from Europe. It conducts anonymous patient surveys, reported outcomes, and historical therapy analysis to deliver real-time feedback and insights. The system fosters collaboration among patients, professionals, and industry for optimized treatment decisions.
TOM Medications is a platform managing therapy and medications for 400,000 patients while supplying pharmaceutical and healthcare sectors with real-world data from Europe. It conducts anonymous patient surveys, reported outcomes, and historical therapy analysis to deliver real-time feedback and insights. The system fosters collaboration among patients, professionals, and industry for optimized treatment decisions.
HQ CountrySwitzerlandSwitzerland
HQ City
Zurich
Zurich
Deal Date25 Jan 202310 Sep 2021
RoundStrategic investmentSeed
Raised$1M$2M
InvestorsGalenicaGalenica; Sanitas Disruptive
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Galenica investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Galenica

When was Galenica founded?Galenica was founded in 1927.
Where is Galenica headquartered?Galenica is headquartered in Switzerland.
How many employees does Galenica have?As of today, Galenica has over 8K employees.
Is Galenica publicly listed?Yes, Galenica is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Galenica?Galenica trades under GALE ticker.
When did Galenica go public?Galenica went public in 2017.
Who are competitors of Galenica?Galenica main competitors include Sigma Foods, WPG Holdings, SiteOne, MSC Industrial Direct, MonotaRO, Bidvest Group, SFS Group, Reece, Synnex Group, Resideo.
What is the current market cap of Galenica?Galenica's current market cap is $5B.
What is the current revenue of Galenica?Galenica's last 12 months revenue is $5B.
What is the current revenue growth of Galenica?Galenica revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Galenica?Current revenue multiple of Galenica is 1.0x.
Is Galenica profitable?Yes, Galenica is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Galenica?Galenica's last 12 months EBITDA is $440M.
What is Galenica's EBITDA margin?Galenica's last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of Galenica?Current EBITDA multiple of Galenica is 12.3x.
What is the current FCF of Galenica?Galenica's last 12 months FCF is $291M.
What is Galenica's FCF margin?Galenica's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Galenica?Current FCF multiple of Galenica is 18.6x.
How many companies Galenica has acquired to date?As of May 2026, Galenica has acquired 4 companies.
What was the largest acquisition by Galenica?$2B acquisition of Relypsa on 21st July 2016 was the largest M&A Galenica has done to date.
What companies Galenica acquired?Galenica acquired Relypsa, Aquantic AG, labor team, and Bichsel Group.
In how many companies Galenica has invested to date?As of May 2026, Galenica has invested in 1 company.
What was the last Galenica investment?On 25th January 2023 Galenica invested in TOM Medications, participating in a $1M Strategic investment round.
In what companies Galenica invested in?Galenica invested in TOM Medications.

See public comps similar to Galenica

Lists including Galenica

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial